Introduction {#sec1}
============

The emergence of antimicrobial resistances (AMR) stimulated the research and development of alternatives to antibiotics, including antibodies, peptides, endolysins, and bacteriophages. Bacteriophages have very desirable characteristics, such as their ability to propagate at the site of infection and low toxicity ([@ref58]). However, phages also have drawbacks inherent with their nature as replicating viruses, such as their limited host range, and the high rate of phage-resistant mutants. These drawbacks complicate manufacturing through the need for phage cocktails. The stability of these cocktails can vary, an effect which recently contributed to the failure of a clinical trial ([@ref35]). The need for propagation on bacteria results in challenges in the purification, a drawback shared with some other biopharmaceuticals. The formulation of phages in a drug product has been characterized only for few applications ([@ref7], [@ref8],[@ref9], [@ref6]; [@ref49]). In order to achieve a broader application in humans, phage therapy must comply with the strict regulations for pharmaceutical products, which have not been developed with phages in mind, so that the application of these regulations poses challenges of its own ([@ref59]). In this article, we will systematically review literature on solutions for technical challenges associated with the production of phages under the international guidelines of Good Manufacturing Practice (GMP).

Legal Framework {#sec2}
===============

In Europe, the directive 2001/83/EC provides the framework for regulations on pharmaceuticals and medicinal products, and clinical trials are regulated by the directive 2001/20/EC and regulation No 536/2014. These were implemented as national legislation in all member states of the European Union. In the USA, Title 21 of the Code of Federal Regulations (21 CFR) regulates current Good Manufacturing Practice (cGMP) and clinical trials. To define more detailed requirements, the European, US, Japanese, and other regulatory bodies adopted common guidelines to harmonize the development and production of pharmaceuticals, through the International Conference on Harmonization (ICH). For the scope of this review, the most important ICH guidelines are [@ref31], which defines cGMP as well as underlying guidelines [@ref27], [@ref28] (Biotechnological Products), Q8(R2) (Pharmaceutical Development), [@ref33] (Quality Risk management), and [@ref23] (Quality System).

So far, every modern controlled trial of a fixed phage product that was designed to establish efficacy failed to demonstrate it ([@ref67]; [@ref35]). However, literature suggests that for specific indications, phage therapy could prove to be even superior to the current standard of care ([@ref19]). To establish phage therapy as a first-line treatment in these cases, marketing authorization as a pharmaceutical and production in GMP will likely be required. Recently, registration of some phages as magistral ingredients, for which GMP and the above guidelines are currently not applicable, was implemented in Belgium, and these were applied to individual patients ([@ref60]; [@ref16]). It is still open whether this approach can achieve wide-spread use internationally also in cases where a scientifically validated standard of care can be expected to be effective (e.g., where bacteria are susceptible to antibiotics), meaning outside of the last resort cases of Article 37 of the Helsinki Declaration. If the magisterial route will be applied on a larger scale and many different parties start producing phage products for patients, we expect that GMP or something close will be demanded by the authorities to safeguard patient safety. Therefore, we will focus this mini-review on phages produced under GMP.

Quality Standards {#sec3}
=================

Quality by Design (QbD) is regarded as the most effective concept for establishing a robust process for the manufacture of drug products (DP) that are consistently effective and safe ([@ref32]; [@ref14]). The development of a manufacturing process following QbD starts by identifying the Quality Target Product Profile (QTPP), i.e., the intended clinical setting, administration route, dosage, container system, and storage of the DP ([@ref81]). The QTPP delineates the Critical Quality Attributes (CQAs), the biological, chemical, microbiological, and physical characteristics that the product must have. For bacteriophages-based DP, the CQAs would typically include identity, absence of contaminating phages, titers of each phage present in the cocktail, maximum level of bacterial toxins and other contaminants, pH, sterility, and shelf life ([@ref58]). The systematic development under QbD follows the concept of the Design Space (DS), a "multidimensional combination and interaction of input variables and process parameters that have been demonstrated to provide assurance of quality." The dimensionality of the DS is determined by the Critical Process Parameters (CPPs), the understanding of which allows to consistently meet the specifications of the CQAs, throughout the product life cycle and even after changes in external factors. In contrast, a rigid definition of the production process, relying on the knowledge of only few variables, can lead to failures in product quality when changes have unforeseen effects ([@ref14]).

Selected Elements of the Design Space for Phage-Based Pharmaceuticals {#sec4}
=====================================================================

Identity of the Phage and the Bacterial Production Strains {#sec5}
----------------------------------------------------------

Only phages that do not contain genetic elements encoding for lysogeny, antimicrobial resistance, and virulence factors are currently considered suited for phage therapy ([@ref58]), which can be confirmed by sequencing and transduction tests. A potential concern is also contamination with phages not intended as active ingredient (AI), which can interfere with the fermentation process or even overgrow the AI phages. The contaminations can arise from the raw materials (water or nutrients), from cross-contaminations with other phages used in the same production facilities, or from induction of prophages from the host bacterial strain ([@ref37]; [@ref44]; [@ref66]). Therefore, the risk of contaminating phages must first be assessed during the process design, and the results must be used to design appropriate quality controls (QCs). The DS must include strategies to avoid contamination with non-intended phages. Also the host strain used for production strongly influences the phage purification process, and should be thoroughly characterized as part of the process development.

Use of Genetically Modified Bacterial Strains for Phage Production {#sec6}
------------------------------------------------------------------

While the pathway for regulatory approval of genetically modified (GM) phages remains largely unexplored, phages genetically "cured" of lysogeny were successfully used to treat a patient ([@ref15]). The use of GM bacterial hosts might be easier to adopt, since they are already approved and in use in other sectors ([@ref43]; [@ref45]; [@ref83]), and there are detailed guidelines for their use (ICH Q5; [@ref29], [@ref30]; [@ref34]). Genetic modifications of the bacterial host can improve phage titers, ease the purification process ([@ref10]), or "detoxify" the host, for example by removing prophages ([@ref3]; [@ref72]; [@ref18]).

Fermentation Process {#sec7}
--------------------

Generally, fermentation process parameters are mainly optimized to improve the phage titer, to increase the phage/impurity ratio, and to reduce the overall cost of production. Bacterial and phage inocula, type of nutrients, agitation/oxygenation, and temperature strongly influence the phage titer ([@ref2]). In addition, an increase of the pH to 8.0 significantly decreased the expression of enterotoxin in *S. aureus* fermentations ([@ref52]). Industrial-scale fermentation of phages would typically be carried out in bioreactors, in fed-batch, continuous ([@ref47]), or semi-batch ([@ref68]) mode. Of these, the latter has the distinct advantage to allow for a continuous production mode while avoiding co-evolution of phages and bacteria ([@ref53]; [@ref39]; [@ref82]).

Purification of Phages {#sec8}
----------------------

The purification process must be designed to consistently achieve the CQA specifications. Among the substances which most strongly influence the safety of the DP are endotoxins, which can also be introduced through raw materials and water. Bacterial toxins such as enterotoxins, alpha-toxin, and several enzymes are also undesired ([@ref56]). Microbial DNA of various species, other bacterial compounds, and phage dsRNA can induce inflammation ([@ref21]; [@ref12]; [@ref20]; [@ref74]). Some phages degrade the DNA of the host, however, not consistently to a safe level ([@ref42]). Proteases should be removed as they could negatively influence the shelf life of the DP.

Depending on the QTTP, the purification has to occur in multiple steps. The sterile filtered lysate can be pre-treated with enzymes, for example, to ease the downstream processes and remove contaminants ([@ref40]). For purification, CsCl gradient centrifugation is routinely used by many academic labs, however, it suffers from low separation power compared to other methods and low scalability ([@ref51]). Ultrafiltration is a highly scalable alternative and very effective in separating phages from smaller impurities ([@ref38]). However, separation of phages from endotoxin is more challenging, since it forms micelles that are of similar size or even larger than phages ([@ref57]). Thus, especially for Gram-negative phage lysates, additional purification steps like different types of ion-exchange chromatography ([@ref4]; [@ref41]), affinity chromatography ([@ref10]), or solvent extraction ([@ref75]) have been proposed to remove endotoxin and other residual contaminants, and the best choice may vary by phage ([@ref76]).

Formulation for Phage-Based Products Including Stability {#sec9}
--------------------------------------------------------

For phages, many formulations ranging from sterile liquids to non-sterile oral liquids, oral solids, semisolids, and patches have been described, depending on the application ([@ref46]). Despite these examples, literature data regarding formulation for phage-based products is scarce. Studies on formulations used for Adeno-associated virus vectors (AAV), which are somewhat related to bacteriophages from a biochemical perspective, can be considered as a reference ([@ref63]). A complete review of formulations is beyond the scope of this review; therefore, we will focus on particularly relevant aspects. A typical challenge with liquid formulations is the stability of the phages. This has contributed to the failing of the PhagoBurn trial, where the instability was discovered only during the trial ([@ref35]). Low stability/decreasing potency of viruses can be the result of aggregation, adsorption to the primary container, chemical degradation, or oxidation ([@ref63]). Aggregation is induced mainly by electrostatic interactions, and can be prevented with charged excipients, certain non-ionic surfactants, or pH optimization. Oxidation can be reduced by anti-oxidants ([@ref63]). In fact, AAV-DP typically contains buffer, antioxidants, surfactants tonicity agents, and cryoprotectants if the DP is intended for storage under frozen conditions ([@ref63]). To define the right balance of excipients experimentally, QbD principles require a significant effort in testing the stability of the AI (all phages in case of a cocktail) formulated as the final DP, inside the primary container.

Quality Controls {#sec10}
================

QCs ensure that the DP fulfills the specifications of the CQAs regarding the AI, the formulation and primary container, as derived from the QTTP. The guidelines [@ref17] 1 and [@ref24] define the design and validation of analytical methods, and the [@ref26] and [@ref25] series for guidelines define specific tests. In the following, we will review the types of QCs, which are expected to be applicable to most phage products.

Identity {#sec11}
--------

As described above, the identity of each phage as an AI is a CQA, with regards to the specific genomic sequence of the phage. The identity of each phage in the master seed bank needs to be demonstrated by NGS ([@ref58]). The maximum acceptable level of genomic divergence between the master seed lot and the phage population in the propagated DP is not defined in guidelines and therefore needs to be aligned with the authorities case by case. While random mutations during propagation are unavoidable, they need to be limited as much as possible through the design of the process, and the functional properties need to be tested with validated QCs, as even individual SNPs can lead to significant phenotypic changes ([@ref5]). Metagenomics has been proposed as QC for some vaccines ([@ref55]; [@ref11]; [@ref22]; [@ref78]), and has also been used to evaluate the composition of commercial phage products ([@ref48]; [@ref77]), or for the detection of phages and bacteria in fermentation processes ([@ref73]; [@ref66]; [@ref13]). Depending on the risk, QCs for the identity of the AI-phage and phage contaminants might be required for each batch of DP. However, in this case, instead of NGS, a highly discriminating PCR-based genotyping technique might be sufficient ([@ref58]).

Titer {#sec12}
-----

The titer of each individual phage in the DP is typically assessed by the double agar layer method (DAL). An alternative to DAL are time-kill assays, where the kinetics of the phage-induced lysis is assessed by measuring the optical density ([@ref80]; [@ref61]; [@ref520]). Other methods, such as qPCR and ELISA, can be used to determine the phage titer, but they rely on the quantification of single components, while the DAL and time-kill assays determine the actual functional virions ([@ref58]).

General Purity {#sec13}
--------------

For biopharmaceuticals, the purity and correct composition of the DP is typically assessed by high performance liquid chromatography, if required coupled with mass spectrometry ([@ref65]). These methods can also be used to identify the phage capsid proteins, toxins, or other bacterial proteins ([@ref63]). Due to the safety risk posed by the production in pathogenic bacteria, CQAs need to specify maximum levels for specific contaminants like endotoxin, enterotoxins, or bacterial DNA, which typically have to be tested with specific, appropriate methods.

Endotoxin {#sec14}
---------

Given the importance of the endotoxin testing, several *in vitro* methods have been developed: gel-clot, turbidimetric, and chromogenic methods. Among the chromogenic methods the Limulus Amebocyte Lysate (LAL) assay is the most frequently used ([@ref1]). When the LAL assay is not applicable, e.g., due to the masking effect, a reporter cell line can be used ([@ref70]).

Contamination by Toxic Bacterial Proteins {#sec15}
-----------------------------------------

Several commercial assays can be used to detect toxic bacterial proteins, including ELISAs for enterotoxins, or assays based on reporter cell lines.

Nucleic Acid Contaminants {#sec16}
-------------------------

Depending on the extent that the phage already degrades bacterial DNA, QCs might be required to demonstrate that the nucleic acid concentration in the DP meets the specifications. The presence and concentration of residual nucleic acids can be tested by qPCR or by using reporter cell lines.

Other Quality Controls {#sec17}
----------------------

The current standard to check sterility or microbial contaminations of pharmaceuticals should be applied to phage-based pharmaceuticals as well ([@ref71]). Other specifications, which might need to be tested include pH, osmolarity, and visual appearance ([@ref59]).

Quality System {#sec18}
==============

The requirements to a quality system in pharmaceutical manufacturing are described in the guideline ICH Q10. ICH Q10 adds to Q8 (Pharmaceutical Development) and Q9 (risk management) by defining the requirements to ensure consistent product quality and thereby securing patient safety and drug efficacy. The quality system described in ICH Q10 consists of four elements: (1) a process performance and product quality monitoring system, (2) a corrective and preventative action (CAPA) system, (3) a change management system, and (4) a management review process. The guideline defines that the most senior leadership level of the company responsible for the process is ultimately accountable for product quality, so that management has the responsibility to own and operate the quality system. Importantly, the guideline also clarifies that these elements should be applied in a manner that is proportionate and appropriate for the life cycle stage the product is in.

Existing Experience in Good Manufacturing Practice Production of Phage Cocktails {#sec19}
================================================================================

To the best of our knowledge, robust phage production processes designed according to the QbD principles are not reported. Only one study describes a quality controlled small-scale production process of a phage cocktail intended for human use, which however was not designed under GMP ([@ref50]). There are several reports of clinical trials where GMP produced cocktails of phages against *P. aeruginosa*, *S. aureus*, and *E. coli* were used ([@ref79]; [@ref62]; [@ref67]; [@ref35], NCT03395769, NCT03395743) or are being used (NCT02664740, NCT03808103). While these reports do not disclose details of the DS for the respective cocktails, they demonstrate that several organizations succeeded in getting clinical trials with GMP phage cocktails approved by regulatory bodies. Furthermore, all these cases and trials demonstrated excellent safety profiles, and no adverse events have been reported.

A Robust Process vs. Low-Cost Production: Is it Really Either Or? {#sec20}
=================================================================

In general, developing a robust process according to the QbD principles will increase the cost of development ([@ref69]). However, QbD will also lead to lower production cost, by reducing the risk of rejected batches, the cost of documenting process deviations, managing CAPAs, and the registration cost for process changes. The emerging phage industry will need to find the right balance for these opposing influences. Moreover, also the regulators will influence production cost, for example through the risk-based decision on the exact purity specifications. This will determine the number of purification steps, the level of process control required to consistently achieve these specifications, and the number and type of QCs, which will have to be conducted and reviewed. In fact, some reports show that adverse events were also not observed where only the endotoxin was removed from the raw lysate with Endotrap columns ([@ref50]; [@ref64]), indicating that, at least in these cases, this process was sufficient for patient safety. Ultimately, a robust process helps ensure that the product is consistently safe and effective, and the investment needed to develop it will have to be commensurate to the intended patient population and route of administration.

Conclusions {#sec21}
===========

The ultimate goal for organizations developing phage therapy should be the wide-spread use of safe and efficacious products for the benefit of patients, even as first-line treatment. Comparing phage-based pharmaceuticals against anything less than the highest standards set by regulators would invite doubts on their effectiveness and safety. This review argues that robust production processes should be feasible for the most important aspects of production of phages. Demonstrating that phage-based drugs are effective and safe also under EMA or FDA standards is the "next level challenge" for the emerging industry. We expect that once this challenge has been overcome for first proof-of-concept examples, many more phage-based pharmaceuticals will reach the market and phages will finally reclaim their place in global medicine.
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